Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Allergy and Immunology | 3 | 2018 | 240 | 1.57 | Why? |
| Th17 Cells | 4 | 2019 | 657 | 1.12 | Why? |
| Arthritis, Juvenile | 4 | 2019 | 191 | 1.07 | Why? |
| Th1 Cells | 3 | 2019 | 1228 | 1.03 | Why? |
| Publishing | 3 | 2018 | 990 | 1.00 | Why? |
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 2 | 2018 | 24 | 0.96 | Why? |
| T-Box Domain Proteins | 1 | 2018 | 62 | 0.76 | Why? |
| STAT5 Transcription Factor | 1 | 2017 | 34 | 0.70 | Why? |
| Subject Headings | 1 | 2017 | 2 | 0.70 | Why? |
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2017 | 96 | 0.65 | Why? |
| Myeloid Cells | 1 | 2020 | 808 | 0.58 | Why? |
| Dendritic Cells | 3 | 2020 | 1330 | 0.57 | Why? |
| T-Lymphocyte Subsets | 2 | 2018 | 1387 | 0.55 | Why? |
| Eosinophils | 1 | 2017 | 848 | 0.43 | Why? |
| Hypersensitivity | 2 | 2018 | 1137 | 0.42 | Why? |
| Immunity, Humoral | 2 | 2021 | 4849 | 0.38 | Why? |
| Carrier State | 1 | 2020 | 2100 | 0.37 | Why? |
| T-Lymphocytes | 4 | 2020 | 6670 | 0.36 | Why? |
| Lymphocytes | 2 | 2017 | 3056 | 0.34 | Why? |
| Interleukin-17 | 3 | 2018 | 602 | 0.34 | Why? |
| Inflammation | 4 | 2018 | 13255 | 0.34 | Why? |
| Asthma | 3 | 2018 | 4383 | 0.24 | Why? |
| Cell Plasticity | 2 | 2019 | 75 | 0.24 | Why? |
| Nasopharynx | 1 | 2020 | 10224 | 0.22 | Why? |
| Cells, Cultured | 5 | 2018 | 5835 | 0.21 | Why? |
| Chemokines, CC | 1 | 2000 | 79 | 0.21 | Why? |
| Lymphoid Tissue | 1 | 2020 | 162 | 0.20 | Why? |
| Thymus Gland | 1 | 2000 | 126 | 0.20 | Why? |
| Immunity, Innate | 1 | 2017 | 6570 | 0.19 | Why? |
| Semen | 2 | 2021 | 550 | 0.19 | Why? |
| Cytotoxicity, Immunologic | 1 | 2020 | 287 | 0.18 | Why? |
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2018 | 49 | 0.18 | Why? |
| Janus Kinase 1 | 1 | 2020 | 254 | 0.18 | Why? |
| Janus Kinase 2 | 1 | 2020 | 218 | 0.18 | Why? |
| Hypereosinophilic Syndrome | 1 | 2018 | 33 | 0.18 | Why? |
| Basophils | 1 | 2018 | 179 | 0.18 | Why? |
| Protein Phosphatase 2 | 1 | 2017 | 18 | 0.18 | Why? |
| Immunologic Techniques | 1 | 2017 | 71 | 0.17 | Why? |
| Carbonic Anhydrase IX | 1 | 2016 | 11 | 0.17 | Why? |
| Peer Influence | 1 | 2017 | 24 | 0.17 | Why? |
| Carbonic Anhydrases | 1 | 2016 | 13 | 0.17 | Why? |
| Societies, Scientific | 1 | 2020 | 414 | 0.16 | Why? |
| Endothelial Progenitor Cells | 1 | 2018 | 103 | 0.16 | Why? |
| Synovial Membrane | 1 | 2016 | 72 | 0.16 | Why? |
| Transplantation, Autologous | 1 | 2018 | 364 | 0.16 | Why? |
| Myeloproliferative Disorders | 1 | 2021 | 507 | 0.16 | Why? |
| Receptors, Immunologic | 1 | 2020 | 555 | 0.16 | Why? |
| Angioedema | 1 | 2018 | 111 | 0.16 | Why? |
| Omalizumab | 1 | 2018 | 158 | 0.16 | Why? |
| Cell Differentiation | 2 | 2018 | 1338 | 0.15 | Why? |
| Clinical Deterioration | 1 | 2020 | 473 | 0.15 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2020 | 724 | 0.15 | Why? |
| Peer Review | 1 | 2018 | 204 | 0.15 | Why? |
| Compassionate Use Trials | 1 | 2020 | 632 | 0.15 | Why? |
| STAT3 Transcription Factor | 1 | 2017 | 268 | 0.15 | Why? |
| Financial Support | 1 | 2017 | 170 | 0.15 | Why? |
| Interleukin-2 | 1 | 2017 | 443 | 0.15 | Why? |
| Respiration | 1 | 2020 | 729 | 0.14 | Why? |
| Nerve Tissue Proteins | 1 | 2017 | 319 | 0.14 | Why? |
| Bone Marrow Transplantation | 1 | 2018 | 343 | 0.14 | Why? |
| T-Lymphocytes, Helper-Inducer | 1 | 2018 | 497 | 0.14 | Why? |
| Janus Kinase Inhibitors | 1 | 2020 | 682 | 0.14 | Why? |
| Education, Professional | 1 | 2017 | 128 | 0.14 | Why? |
| Flow Cytometry | 2 | 2020 | 2393 | 0.14 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 9335 | 0.13 | Why? |
| Lipids | 1 | 2021 | 1079 | 0.13 | Why? |
| Pyrazoles | 2 | 2021 | 1791 | 0.13 | Why? |
| Phosphorylation | 1 | 2017 | 1060 | 0.13 | Why? |
| Anti-Asthmatic Agents | 1 | 2018 | 427 | 0.13 | Why? |
| Mice, Knockout | 1 | 2018 | 1815 | 0.13 | Why? |
| Up-Regulation | 2 | 2018 | 2249 | 0.12 | Why? |
| Interleukin-6 | 2 | 2020 | 7522 | 0.12 | Why? |
| DNA | 1 | 2017 | 778 | 0.11 | Why? |
| Peptide Hydrolases | 1 | 2019 | 1269 | 0.11 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.11 | Why? |
| Leukocyte Count | 2 | 2018 | 3178 | 0.11 | Why? |
| Epithelial Cells | 2 | 2018 | 3508 | 0.11 | Why? |
| Interferon-gamma | 2 | 2018 | 2711 | 0.10 | Why? |
| Immune Evasion | 1 | 2020 | 2081 | 0.10 | Why? |
| Humans | 32 | 2021 | 930598 | 0.10 | Why? |
| RNA | 1 | 2017 | 1278 | 0.10 | Why? |
| Ischemia | 1 | 2018 | 901 | 0.10 | Why? |
| Immunologic Memory | 1 | 2021 | 3362 | 0.09 | Why? |
| Adenine | 1 | 2011 | 463 | 0.09 | Why? |
| Toll-Like Receptor 7 | 1 | 2011 | 402 | 0.08 | Why? |
| International Cooperation | 1 | 2020 | 3436 | 0.08 | Why? |
| Nitriles | 2 | 2021 | 1053 | 0.08 | Why? |
| Serine Endopeptidases | 1 | 2020 | 4606 | 0.07 | Why? |
| Guidelines as Topic | 1 | 2017 | 2844 | 0.07 | Why? |
| Interleukin-10 | 1 | 2011 | 1409 | 0.07 | Why? |
| Animals | 5 | 2020 | 78931 | 0.06 | Why? |
| Periodicals as Topic | 1 | 2017 | 1492 | 0.06 | Why? |
| Mice | 3 | 2018 | 21357 | 0.06 | Why? |
| Pyrimidines | 2 | 2021 | 1557 | 0.06 | Why? |
| Information Dissemination | 1 | 2018 | 2986 | 0.06 | Why? |
| Viral Proteins | 1 | 2020 | 7370 | 0.06 | Why? |
| Virus Internalization | 1 | 2020 | 7921 | 0.06 | Why? |
| Chemokine CCL22 | 1 | 2000 | 4 | 0.06 | Why? |
| Chemokine CCL21 | 1 | 2000 | 5 | 0.06 | Why? |
| Chemokine CCL19 | 1 | 2000 | 22 | 0.06 | Why? |
| Combined Modality Therapy | 2 | 2020 | 3395 | 0.05 | Why? |
| Female | 13 | 2021 | 380317 | 0.05 | Why? |
| Kidney Transplantation | 1 | 2021 | 5397 | 0.05 | Why? |
| Fever | 1 | 2018 | 7795 | 0.05 | Why? |
| Ki-1 Antigen | 1 | 2000 | 25 | 0.05 | Why? |
| Chemotaxis, Leukocyte | 1 | 2000 | 82 | 0.05 | Why? |
| Leukocyte Common Antigens | 1 | 2000 | 101 | 0.05 | Why? |
| Protein Binding | 1 | 2017 | 11430 | 0.05 | Why? |
| Semen Analysis | 1 | 2021 | 235 | 0.05 | Why? |
| Granzymes | 1 | 2020 | 197 | 0.05 | Why? |
| Europe | 1 | 2017 | 12702 | 0.05 | Why? |
| Cartilage, Articular | 1 | 2019 | 50 | 0.05 | Why? |
| Receptors, IgE | 1 | 2018 | 26 | 0.05 | Why? |
| Adult | 7 | 2021 | 244371 | 0.05 | Why? |
| Cell Enlargement | 1 | 2018 | 3 | 0.05 | Why? |
| PAX2 Transcription Factor | 1 | 2018 | 2 | 0.05 | Why? |
| Community-Institutional Relations | 1 | 2020 | 164 | 0.05 | Why? |
| Ploidies | 1 | 2018 | 5 | 0.05 | Why? |
| PAX8 Transcription Factor | 1 | 2018 | 7 | 0.05 | Why? |
| Cell Dedifferentiation | 1 | 2018 | 7 | 0.05 | Why? |
| Synovial Fluid | 1 | 2019 | 64 | 0.05 | Why? |
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2021 | 277 | 0.05 | Why? |
| CD40 Ligand | 1 | 2018 | 121 | 0.05 | Why? |
| Interleukin-5 | 1 | 2018 | 138 | 0.04 | Why? |
| Male | 12 | 2021 | 367725 | 0.04 | Why? |
| Adult Stem Cells | 1 | 2018 | 68 | 0.04 | Why? |
| Lysophospholipids | 1 | 2018 | 74 | 0.04 | Why? |
| Aged | 8 | 2021 | 215776 | 0.04 | Why? |
| Acute Kidney Injury | 1 | 2018 | 5762 | 0.04 | Why? |
| Histone Deacetylase Inhibitors | 1 | 2018 | 79 | 0.04 | Why? |
| Sphingosine | 1 | 2018 | 101 | 0.04 | Why? |
| Cell Lineage | 1 | 2018 | 241 | 0.04 | Why? |
| Cell Cycle | 1 | 2018 | 329 | 0.04 | Why? |
| Bone Marrow Cells | 1 | 2018 | 186 | 0.04 | Why? |
| Extremities | 1 | 2018 | 179 | 0.04 | Why? |
| Bone and Bones | 1 | 2019 | 235 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
| Kidney Tubules | 1 | 2018 | 205 | 0.04 | Why? |
| Cell Separation | 1 | 2017 | 270 | 0.04 | Why? |
| RNA, Messenger | 2 | 2021 | 5131 | 0.04 | Why? |
| Amputation | 1 | 2018 | 331 | 0.04 | Why? |
| Immunoglobulin E | 1 | 2018 | 557 | 0.04 | Why? |
| Ligands | 1 | 2000 | 1300 | 0.04 | Why? |
| Leukocytes, Mononuclear | 2 | 2018 | 2115 | 0.04 | Why? |
| Models, Immunological | 1 | 2020 | 727 | 0.04 | Why? |
| Regeneration | 1 | 2018 | 429 | 0.03 | Why? |
| Cytokines | 2 | 2020 | 15010 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.03 | Why? |
| Mice, Inbred C57BL | 2 | 2018 | 5542 | 0.03 | Why? |
| Quality Control | 1 | 2017 | 628 | 0.03 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.03 | Why? |
| Biomarkers | 3 | 2020 | 23361 | 0.03 | Why? |
| Immunophenotyping | 1 | 2017 | 1290 | 0.03 | Why? |
| Receptors, Interleukin-6 | 1 | 2020 | 1383 | 0.03 | Why? |
| False Positive Reactions | 1 | 2017 | 1338 | 0.03 | Why? |
| Down-Regulation | 1 | 2018 | 1416 | 0.03 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.03 | Why? |
| Injections, Intraperitoneal | 1 | 2011 | 69 | 0.03 | Why? |
| Galactosylceramides | 1 | 2011 | 22 | 0.03 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.03 | Why? |
| B-Lymphocytes | 2 | 2020 | 4418 | 0.03 | Why? |
| Molecular Structure | 1 | 2016 | 1539 | 0.03 | Why? |
| Mice, Transgenic | 1 | 2018 | 2739 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2020 | 4260 | 0.03 | Why? |
| Lung | 2 | 2017 | 31049 | 0.03 | Why? |
| Patient Education as Topic | 1 | 2020 | 1476 | 0.03 | Why? |
| Killer Cells, Natural | 1 | 2020 | 2093 | 0.03 | Why? |
| Aged, 80 and over | 4 | 2020 | 88759 | 0.03 | Why? |
| Cell Proliferation | 1 | 2017 | 1973 | 0.02 | Why? |
| Interleukin-13 | 1 | 2011 | 204 | 0.02 | Why? |
| Middle Aged | 7 | 2021 | 270681 | 0.02 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2019 | 2483 | 0.02 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.02 | Why? |
| Phenotype | 1 | 2019 | 4037 | 0.02 | Why? |
| Single-Cell Analysis | 1 | 2018 | 2450 | 0.02 | Why? |
| Th2 Cells | 1 | 2011 | 680 | 0.02 | Why? |
| Time Factors | 2 | 2020 | 31397 | 0.02 | Why? |
| Critical Care | 2 | 2020 | 14081 | 0.02 | Why? |
| Oxygen | 1 | 2020 | 3715 | 0.02 | Why? |
| Comorbidity | 2 | 2020 | 34796 | 0.02 | Why? |
| Software | 1 | 2017 | 2501 | 0.02 | Why? |
| Prospective Studies | 2 | 2021 | 43301 | 0.02 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4545 | 0.02 | Why? |
| Transplant Recipients | 1 | 2021 | 4982 | 0.02 | Why? |
| Survival Analysis | 1 | 2018 | 7592 | 0.02 | Why? |
| Child, Preschool | 2 | 2016 | 36283 | 0.02 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.02 | Why? |
| Treatment Outcome | 2 | 2020 | 51732 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.02 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2020 | 5837 | 0.02 | Why? |
| Length of Stay | 1 | 2020 | 11042 | 0.01 | Why? |
| Research Design | 1 | 2017 | 5830 | 0.01 | Why? |
| Pandemics | 4 | 2020 | 389249 | 0.01 | Why? |
| Immunoglobulin M | 1 | 2018 | 9091 | 0.01 | Why? |
| Gene Expression | 1 | 2011 | 3332 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2018 | 17020 | 0.01 | Why? |
| Viral Load | 1 | 2020 | 15850 | 0.01 | Why? |
| Viral Vaccines | 1 | 2020 | 7560 | 0.01 | Why? |
| Infant, Newborn | 1 | 2000 | 23105 | 0.01 | Why? |
| Retrospective Studies | 2 | 2020 | 105322 | 0.01 | Why? |
| Child | 2 | 2019 | 70012 | 0.01 | Why? |
| Young Adult | 2 | 2020 | 93724 | 0.01 | Why? |
| Adolescent | 2 | 2019 | 86841 | 0.01 | Why? |
| Infant | 1 | 2000 | 30274 | 0.01 | Why? |
| Global Health | 1 | 2020 | 13911 | 0.01 | Why? |
| Italy | 1 | 2020 | 38444 | 0.01 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.01 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.01 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 7868 | 0.01 | Why? |
| Cohort Studies | 1 | 2018 | 36005 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2021 | 53120 | 0.01 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 13720 | 0.01 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.01 | Why? |
Annunziato's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(216)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(162)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_